Menu Search
Equities

Neuren Pharmaceuticals Ltd

NK9:DEU

Neuren Pharmaceuticals Ltd

Actions
  • Price (--)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta--
--
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in AUDIncome statement in AUDView more

Year on year Neuren Pharmaceuticals Ltd grew revenues 1,403.22% from 15.81m to 237.63m while net income improved 85,270.11% from 184.00k to 157.08m.
Gross margin--
Net profit margin57.44%
Operating margin81.30%
Return on assets72.03%
Return on equity75.51%
Return on investment75.50%
More ▼

Cash flow in AUDView more

In 2023, cash reserves at Neuren Pharmaceuticals Ltd fell by 23.09m. However, the company earned 184.93m from its operations for a Cash Flow Margin of 77.82%. In addition the company generated 3.62m cash from financing while 211.49m was spent on investing.
Cash flow per share0.9072
Price/Cash flow per share13.54
Book value per share1.71
Tangible book value per share1.71
More ▼

Balance sheet in AUDView more

Neuren Pharmaceuticals Ltd uses little or no debt in its capital structure.
Current ratio25.42
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.